The podocyte as a direct target for treatment of glomerular disease?
The Centers for Disease Control and Prevention estimates more than 10% of adults in the United States, over 20 million Americans, have chronic kidney disease (CKD). A failure to maintain the glomerular filtration barrier directly contributes to the onset of CKD. The visceral epithelial cells, podocytes, are integral to the maintenance of this renal filtration barrier. Direct podocyte injury contributes to the onset and progression of glomerular diseases such as minimal change disease (MCD), focal segmental glomerular sclerosis (FSGS), diabetic nephropathy, and HIV-associated nephropathy (HIVAN). Since podocytes are terminally differentiated with minimal capacity to self-replicate, they are extremely sensitive to cellular injury. In the past two decades, our understanding of the mechanism(s) by which podocyte injury occurs has greatly expanded. With this newfound knowledge, therapeutic strategies have shifted to identifying targets directed specifically at the podocyte. Although the systemic effects of these agents are important, their direct effect on the podocyte proves to be essential in ameliorating glomerular disease. In this review, we highlight the mechanisms by which these agents directly target the podocyte independent of its systemic effects.
Division of Nephrology, Department of Medicine, Stony Brook University, Stony Brook, New York;
Sandeep K
SK
Mallipattu
Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; and Renal Section, James J. Peters VA Medical Center, New York, New York cijiang.he@mssm.edu.
John C
JC
He
D000818:Animals; D065095:Calcineurin Inhibitors / Q000494:pharmacology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology*; D050199:Podocytes / Q000473:pathology*; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy* / Q000473:pathology*
D065095:Calcineurin Inhibitors; D005938:Glucocorticoids
abatacept; calcineurin inhibitors; glucocorticoids; podocyte; rituximab